XML 43 R20.htm IDEA: XBRL DOCUMENT v3.25.2
EARNINGS PER SHARE
 6 Months Ended
Jun. 30, 2025
Earnings Per Share [Abstract]  
EARNINGS PER SHARE
13. EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, nonvested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive.
The table below presents the computation of basic and diluted earnings per share (in millions, except for per share information):
 Three Months Ended
June 30,		Six Months Ended
June 30,
 2025202420252024
Net Income for Earnings Per Share Calculations:
Income from continuing operations, net of tax$335.9 $364.0 $699.5 $688.9 
Net loss attributable to noncontrolling interests(1.7)(1.3)(3.3)(2.2)
Income from continuing operations attributable to Edwards Lifesciences Corporation337.6 365.3 702.8 691.1 
(Loss) income from discontinued operations(4.4)1.0 (11.6)27.1 
Net income attributable to Edwards Lifesciences Corporation$333.2 $366.3 $691.2 $718.2 
Weighted Average Shares:
Basic weighted-average shares outstanding587.0 602.1 586.9 601.8 
Dilutive effect of stock plans0.9 2.2 1.0 2.4 
Dilutive weighted-average shares outstanding587.9 604.3 587.9 604.2 
Earnings per Share:
Basic:
Continuing operations$0.58 $0.61 $1.20 $1.15 
Discontinued operations(0.01)— (0.02)0.04 
Basic earnings per share$0.57 $0.61 $1.18 $1.19 
Diluted:
Continuing operations$0.57 $0.61 $1.20 $1.15 
Discontinued operations(0.01)— (0.02)0.04 
Diluted earnings per share$0.56 $0.61 $1.18 $1.19 

Stock options, restricted stock units, and market-based restricted stock units to purchase an aggregate of 9.6 million and 7.7 million common shares for the three months ended June 30, 2025 and 2024, respectively, and 8.8 million and 6.5 million shares for the six months ended June 30, 2025 and 2024, respectively, were outstanding but were not included in the computation of diluted earnings per share for such periods because the effect would have been anti-dilutive. Additionally, 0.9 million shares that would have been received if the ASR agreement discussed in Note 10 was settled as of June 30, 2025, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive.